← All candidates
26 insider filings on record.
26 filings on record.
KALAKALA BIO, Inc.
NasdaqCM · Healthcare · $14.05M
$0.5720
-6.10% · Sep 15
26 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 10 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what KALA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$14.05M
Float
18.6M
100% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
21 more transactions on Pro →Context
Earnings · EPS vs forecast
3 of 4 quarters beat
Q3 '25−$53.50 act−$3.00
Q2 '25−$65.94 act+$36.06
Q1 '25−$50.66 act+$76.34
Q4 '24−$61.58 act+$61.92
Coverage
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic TestsInvestorsHub · 1w agoKala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing PartnershipInvestorsHub · 2w agoKALA BIO: Q3 Earnings SnapshotAssociated Press Finance · 11-19KALA Stock Crashes 88% in a Month Following Eye Disorder Study FailureZacks · 10-08
The file stays open
26 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice